Introductiontreatment of Type 2 diabetes (T2D)
Pro residue is located at the penultimate position (Kühn-Wache, Bär, Hoffmann, Wolf, Rahfeld & 83 peptides released were then analysed for their potential to act as DPP-IV preferred substrates, i.e., 120 peptides with a Pro residue at the penultimate position. Three casein-derived peptide sequences 121 (Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-Tyr) which contained 122 previously identified DPP-IV inhibitory peptides within their sequence were selected from the in 123 silico digestion with gastrointestinal enzymes. Ile-Pro-Ile-Gln-Tyr contained the potent DPP-IV 124 inhibitor Ile-Pro-Ile which has also been identified as a DPP-IV substrate (Rahfeld et al., 1991) . 125
In addition, its incubation with DPP-IV was predicted to release Ile-Pro, which has been 126 identified as a DPP-IV inhibitor (Hatanaka et al., 2012). Digestion of Leu-Pro-Leu-Pro-Leu and 127
Leu-Pro-Tyr-Pro-Tyr with DPP-IV would theoretically release the previously identified DPP-IV 128 inhibitors Leu-Pro and Tyr-Pro (Hatanaka et al., 2012). Tyr-Pro-Tyr-Tyr (Casoxin B) was used 129 for its structural similarities with Leu-Pro-Tyr-Pro-Tyr. The five peptide sequences were digested 130 in silico with DPP-IV and the resulting peptide products were identified. 131 7 to check the retention of activity at the end of the reaction, DPP-IV was also incubated for 18 h at 143 37C in 100 mM Tris-HCl buffer pH 8.0 without substrate. At the end of the incubation period, 144 this sample was incubated with Gly-Pro-pNA and DPP-IV activity was determined. 145
Milk protein hydrolysates derived from caseins, whey proteins and lactoferrin as described in 146
Nongonierma and FitzGerald (2013) were used in this study. The hydrolysates were resuspended 147 in 100 mM Tris-HCl buffer pH 8.0 at 10 mg.mL -1 (final concentration) and incubated at 37C for 148 24 h with DPP-IV at an E:S of 0.2 and 2 U of DPP-IV.g -1 of hydrolysate. The control consisted of 149 the hydrolysates resuspended in 100 mM Tris-HCl buffer pH 8.0 and incubated at 37C for 24 h 150 without DPP-IV. Hydrolysis with DPP-IV was carried out in duplicate (n=2). 151
DPP-IV inhibition assay 152
Diprotin A was resuspended in HPLC grade water at concentrations ranging from 12.5 × 10 -3 153 to 12.5 µg.mL -1 (final concentration), the other peptides and milk protein hydrolysates were 154 dispersed at concentrations ranging from 12.5 × 10 -3 to 1.25 mg.mL -1 (final concentration). The 155 DPP-IV inhibition assay was carried out as described by Nongonierma and FitzGerald (2013) . 156
Briefly, the test samples (25L) were pipetted onto a 96 well microplate (Sarstedt, Dublin, 157
Ireland) containing Gly-Pro-pNA, the reaction substrate (50 L, final concentration 0.2 mM). 158
The negative control contained 100 mM Tris-HCl buffer pH 8.0 (25L) and the reaction 159 substrate Gly-Pro-pNA. The reaction was initiated by the addition of DPP-IV (50 L, final 160 concentration 0.0025 U.mL -1 ). All the reagents and samples were diluted in 100 mM Tris-HCl 161 buffer pH 8.0. Diprotin A was used as a positive control. Each sample was analysed in triplicate. were determined from the double reciprocal plots. 174
DPPH radical scavenging assay 175
The DPPH assay was used to determine the radical scavenging properties of the peptides 176 which were dispersed in HPLC grade water at concentrations ranging from 1.25 × 10 -2 to 2.5 177 mg.mL -1 . The DPPH scavenging assay was carried out essentially according to Nongonierma 
Statistical analysis 202
Means comparison was carried out using a one way ANOVA followed by a Student Newman-203
Keuls test using SPSS (version 9, SPSS Inc., Chicago, IL, USA) at a significance level P < 0.05. 204
Results 205

In silico gastrointestinal digestion of DPP-IV inhibitory peptides 206
Of the different milk protein-derived peptides identified with DPP-IV preferred substrate 207 features, three peptide sequences Ile-Pro-Ile-Gln-Tyr (κ-casein variant A, f26-30), Leu-Pro-Tyr-208
Pro-Tyr (κ-casein variant A, f56-60) and Leu-Pro-Leu-Pro-Leu (β-casein variant A2, f135-139) 209 were chosen for this study. These were selected on the basis that they contained previously 210 identified DPP-IV inhibitory peptides which may be released during DPP-IV digestion. In 211 addition, Tyr-Pro-Tyr-Tyr (κ-casein variant A, f58-61) which has previously been identified as 212 casoxin B (Chiba, Tani & Yoshikawa, 1989 ) and diprotin A (Ile-Pro-Ile, κ-casein variant A, f26-213 28) were also included in this study. Ile-Pro-Ile, a well-known DPP-IV inhibitor, was used as a 214 positive control as it has previously been identified as a DPP-IV substrate (Rahfeld et al., 1991).
Leu-Pro-Leu, Ile-Pro-Ile-Gln-Tyr, Tyr-Pro-Tyr-Tyr, Leu-Pro-Leu and Tyr-Pro-Tyr) were 248 incubated with DPP-IV at a low and high E:S. After 18 h incubation at 37C with DPP-IV, all 249 peptides were cleaved by the enzyme with the exception of Ile-Gln-Tyr and Pro-Ile (the negative 250 controls) which in theory could not be cleaved by DPP-IV. It was found at the end of the 251 incubation that DPP-IV was still active as 69.3  2.9 % DPP-IV activity was found. The RP-252 UPLC profiles for Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr, Leu-Pro-Leu-Pro-Leu and Leu-Pro-Tyr-Pro-253
Tyr incubated at the low and high E:S are illustrated on Fig. 2 . The RP-UPLC profiles show that 254 these peptides were cleaved to release their predicted breakdown products as per in silico 255 digestion with DPP-IV (section 3.1.). As expected peptide breakdown was more pronounced at 256 the high compared to the low E:S. The same results were found with Tyr-Pro-Tyr-Tyr, Tyr-Pro-257
Tyr and Leu-Pro-Leu (data not shown). 258
Quantification of the peptides in each sample was carried out using the response factors from 259 the calibration curves determined for each individual peptide and amino-acid. The concentration 260 of amino acids and peptides present in each sample is shown in Table 2 . As expected, breakdown 261 of the parent peptide was higher at the high compared to the low E:S. The mass balance of 262 peptides generated during DPP-IV hydrolysis agreed with the concentration of parent peptide 263
cleaved. Some components were not detected in the hydrolysed samples, this was due to the 264 amount of amino acids or peptides being below the detection threshold. Differences were seen in 265 the extent of peptide breakdown depending on the sequence of the parent peptide. At the high 266 E:S, Tyr-Pro-Tyr-Tyr and Tyr-Pro-Tyr were completely cleaved and could not be detected after 267 18 h incubation. In contrast, modest peptide breakdown was seen with Ile-Pro-Ile with less than 268 DPP-IV at 2, 20, 21 and 28 min retention times, where peptide peaks did not match between the 274 control and the hydrolysate incubated with DPP-IV (supplementary Fig. S2 a) . For the whey 275 protein hydrolysate (WPH), one peak eluting at 15 min was absent from the hydrolysate after 276 incubation with DPP-IV (supplementary Fig. S2 b) . In the case of the lactoferrin hydrolysate 277 (LFH), slight differences were seen at 3 and 9 min between the control and after incubation with 278 DPP-IV (supplementary Fig. S2 c) . 279
Overall, incubation of the individual peptides with DPP-IV induced major changes in the 280 peptide composition, whereas for the milk protein hydrolysate, only minor modifications were 281 seen. 282
DPP-IV inhibitory properties of milk protein-derived peptides and milk protein hydrolysates 283 following incubation with DPP-IV 284
The IC 50 values for the peptides pre and post DPP-IV hydrolysis was evaluated to study the 285 impact of peptide breakdown on the bioactive properties (Table 3 ). The IC 50 value of the control 286 samples were similar to the values previously reported for these peptides (Table 1) , suggesting 287 that the bioactive properties of these peptides were not altered following incubation at 37C for 288 18 h. In addition, the RP-UPLC of the peptides in the control and freshly prepared peptides did 289 not differ (data not shown), suggesting that the peptides were not degraded during incubation in 290 the controls. For most peptides, there was no significant difference (P ≥ 0.05) in terms of IC 50 291 value between the control and the low E:S sample, with the exception of Leu-Pro-Leu-Pro-Leu. 292
Leu-Pro-Leu-Pro-Leu had a significantly (P < 0.05) lower IC 50 value at the low E:S compared to 293 the control. For all peptides, incubation with DPP-IV at the high E:S resulted in a significant 294 increase (P < 0.05) in the IC 50 value compared to the control and the low E:S sample. However, 295 this was not seen for Leu-Pro-Leu-Pro-Leu where the IC 50 value significantly decreased (P < 296 0.05) following incubation with DPP-IV and no significant difference (P ≥ 0.05) was seen13 between the IC 50 values at the low and high E:S. 298
The IC 50 values for the milk protein hydrolysates incubated with DPP-IV at a high and low 299 E:S were determined (Fig. 3) . There was no significant difference (P ≥ 0.05) between the IC 50 300 value of the three hydrolysate controls. Following incubation with DPP-IV, no significant 301 differences in terms of IC 50 values were found for WPH and LFH between the control and the 302 high and low E:S digests. In contrast, for CasH, samples incubated with DPP-IV displayed a 303 significantly lower (P < 0.05) IC 50 value compared to CasH control. There was no significant 304 difference (P ≥ 0.05) between CasH incubated at high or low E:S. 305
Discussion 306
This study has demonstrated that milk protein-derived peptides, with a Pro at position 2, 307 predicted to be released by gastrointestinal enzymes could act as DPP-IV inhibitors, involving a 308 substrate or prodrug mode of inhibition. With both substrate or prodrug modes of inhibition, the 309 starting peptides are susceptible to further DPP-IV cleavage, resulting in the release of more or 310 less potent peptide inhibitors as compared to the parent peptide. All peptides studied herein were 311 competitive inhibitors, suggesting a direct interaction of the peptides with the active site of DPP-312
IV. 313
To our knowledge, of the different peptides studied, only Ile-Pro-Ile, Ile-Pro, Tyr-Pro and Leu-314 value compared to Leu-Pro (149.6  6.1 and 712.5  11.0 µM, respectively, Table 1 ). In addition, 317
Ile-Pro was about 6 times more potent than Leu-Pro, which is of the same order as the values 318 reported in Table 1 . In contrast, we found that Tyr-Pro was a more potent DPP-IV inhibitor than 319 Leu-Pro, whereas Hatanaka et al. Table 1) . 338
To our knowledge, no study has identified milk protein-derived peptides with a prodrug-type 339 behavior for DPP-IV inhibition. One peptide, Leu-Pro-Leu-Pro-Leu, had a different behaviour 340 from the other peptides studied herein, showing a decrease in the IC 50 value following incubation 341 at low and high E:S as compared to the control (Table 3 ). This peptide therefore displayed a 342 prodrug-type inhibition according to the classification established by Fujita & Yoshikawa (1999) . 343
In the sample containing Leu-Pro-Leu-Pro-Leu incubated with low and high E:S, significant 344 amounts of Leu-Pro-Leu were found (Table 2 ). This peptide is about 30 % more potent than LeuPro-Tyr was cleaved from Leu-Pro-Tyr-Pro-Tyr, whereas 100 % of Tyr-Pro-Tyr was cleaved 353 with DPP-IV. For Leu-Pro-Leu incubated with DPP-IV, more than 75 % was cleaved whereas 30 354 % Leu-Pro-Leu was cleaved when Leu-Pro-Leu-Pro-Leu was incubated with DPP-IV at the high 355 E:S. These differences may arise from the inhibition exerted by the parent peptide (Leu-Pro-Leu-356
Pro-Leu or Leu-Pro-Tyr-Pro-Tyr) on DPP-IV, which may have blocked further cleavage of Tyr-357
Pro-Tyr and Leu-Pro-Leu. This is further supported by the fact that the more potent DPP-IV 358 inhibitory peptides (i.e. Ile-Pro-Ile, Ile-Pro-Ile-Gln-Tyr and Leu-Pro-Tyr-Pro-Tyr, Table 1 ) 359 studied herein were generally cleaved to a lesser extent by DPP-IV (Table 2 and Fig. 2) . 360
For the whey protein-derived hydrolysates (WPH and LFH), preincubation with DPP-IV did 361 not affect the DPP-IV inhibitory properties of the samples (Fig. 3) . This was in agreement with 362 the fact that the peptide profile for these samples was essentially unaffected by incubation with 363 DPP-IV (supplementary Fig. S2 ). However, with CasH, more obvious modifications were seen in 364 the peptide profile, which resulted in a significant decrease in the DPP-IV inhibitory properties. 365
Differences observed between whey proteins and caseins may come from the fact that caseins 366 contain higher amounts of Pro residues on a weight basis compared to whey. In addition, a higher 367 number of peptides with a Pro at the penultimate position were identified with the in silico 368 approach used herein for the caseins (α s1 -, α s2 -, β-and κ-casein) as compared to the whey proteins 369 (β-lactoglobulin and α-lactalbumin). The significant decrease in the IC 50 value observed with 370
CasH following incubation with DPP-IV may be explained by the fact that it may contain 371 prodrug-type DPP-IV inhibitory peptides. Peptide peaks eluting at the same retention time as 372
Leu-Pro-Leu-Pro-Leu (17.9 min) and Leu-Pro-Leu (12.3 min) were seen on the RP-UPLC profile 373 of CasH. However, there was no difference in peak areas between the control and the high E:Svalue. However, several other peptides which have not been studied herein may be responsible 376 for this effect. Mass spectrometric identification of the peptides within CasH may help to better 377 understand the effect of DPP-IV pre-digestion on the overall DPP-IV inhibitory properties of the 378 casein hydrolysate. 379
To assess if the peptides studied herein also had the potential to reduce oxidative stress in 380 T2D, their antioxidant activity was studied. The peptides evaluated herein only had a modest 381 DPPH scavenging activity. The EC 50 value for DPPH scavenging by the casein-derived peptide 382
Tyr-Pro-Tyr-Pro-Glu-Leu was 98 M while it was 23.3 M for carnosine (Ala-His) (Suetsuna, reach the circulation where they may further display their DPP-IV inhibitory properties. Although 417 the IC 50 value of the larger peptides was generally found to be lower than that of the shorter 418 peptides studied herein, the IC 50 values for shorter peptides indicate that these are still moderately 419 potent inhibitors of DPP-IV (Table 1) . 420
421
Conclusion 422
Milk protein-derived peptides which have been predicted to be released by gastrointestinal 423 enzyme activities have been shown to behave as substrate-or prodrug-type inhibitors of DPP-IV. 424
Besides their DPP-IV inhibitory properties, which make them interesting candidates for 425 protecting incretins against DPP-IV cleavage in the gastrointestinal tract, the instability of theserelease peptides which were in some cases more or less potent DPP-IV inhibitors. It is anticipated 428 Table 3 Concentration of milk protein-derived peptides inducing 50 % inhibition (IC 50 ) of dipeptidyl peptidase IV (DPP-IV) pre-(control) and post-hydrolysis of the milk protein-derived peptides with DPP-IV following incubation at 37C for 18 h at a low (1 U: 1 g peptide) and high (10 U: 1 g peptide) enzyme to substrate ratio (E: S).
